Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial of BT1718 for advanced cancer
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new drug called BT1718 for people with advanced cancer that has spread elsewhere in the body.
Cancer Research UK supports this trial.
More about this trial
Researchers are looking for new ways to treat people with advanced solid tumours when standard treatments have stopped working. In this trial, they are looking at BT1718.
MT1 MMP is a protein. It breaks down other proteins that surround a cell. Cancer cells have higher levels of MT1 MMP than normal cells. This can cause cancer to grow and spread. So, researchers are looking at ways to stop this happening. They think having BT1718 might help.
BT1718 is a type of targeted treatment called a small molecule drug. It recognises and attaches itself to the MT1 MMP protein. This causes the cancer cell to die. As cancer cells have more MT1 MMP on their surface than normal cells, healthy cells are less affected.
This trial is in 2 phases. Phase 1 looked at the best dose of BT1718. Please note, phase 1 is now closed.
Phase 2 will test this dose in a larger number of people. This is part of the trial is open.
This is the first time people have had BT1718.
The main aims of the trial are to find out:
- the best dose of BT1718
- what happens to the drug in the body
- how well treatment works
- more about the side effects
Who can enter
- have an advanced
- have had standard treatments but they stopped working and there isn’t a suitable treatment or you don’t want to have more standard treatments
- have cancer that your doctor can measure on a scan and at least 1 area has got worse since your last scan
- are willing for the trial team to look at any leftover samples from previous tissue samples (
- have high levels of the protein MT1 MMP in your cancer cells
- are willing give a new tissue sample of the cancer before and after you have treatment with BT1718
- have satisfactory blood test results
- are well enough to carry out all your normal activities, apart from heavy physical work (performance status 0 to 1)
- are willing to use 2 forms of reliable contraception during the trial and for 6 months afterwards if there is any chance you or your partner could become pregnant
- are at least 16 years old
- have had radiotherapy unless it was for symptoms (
palliative radiotherapy), hormone treatment, cancer treatment, or any treatment for cancer as part of a clinical trial in the last 4 weeks (or in the last 6 weeks if you had nitrosoureas or mitomycin C)
- have had a
bone marrow transplant, high doses of chemotherapy or radiotherapy to more than one quarter of your bone marrow within 8 weeks of the first dose of BT1718
- have cancer spread to your brain unless you have had treatment, don’t have any symptoms and you haven’t had steroids in the last 4 weeks
- have side effects from past treatments unless they are mild, apart from hair loss or any side effects that your doctor thinks won’t interfere with having treatment
- have or have had any other cancer which could affect you taking part in this trial, apart from
basal cell skin cancer, squamous cell skin cancer, early bladder cancer or carcinoma insitu
- have had surgery and you haven’t fully recovered
- have any other medical condition including an active uncontrolled infection
- have HIV
- have hepatitis B or hepatitis C
- have a serious heart problem such as an abnormal heart rhythm, congestive heart failure or a lack of oxygen and blood flow to the heart (cardiac ischaemia)
- are going to take part in another trial using an experimental drug
- have any other serious medical condition that means you aren’t suitable to take part in this trial
Phase 1 is now closed. 39 people joined this part of the trial. Phase 2 is open. The researchers need up to 70 people to join phase 2.
In phase 1, the first few people taking part had a low dose of BT1718. The next few people had a higher dose if they didn’t have any serious side effects. And so on, until they found the best dose. We call this a dose escalation trial.
Phase 2 is open. This will test the same dose in a larger number of people. This part is for people who have non small cell lung cancer. This is the lung cohort. It will also include some people with other cancer types. Researchers call this a basket cohort.
You have BT1718 as a drip into a vein or you might have it through a small syringe connected to a pump. It takes about 60 minutes each time. You have treatment in cycles. Each 4 week period is a cycle of treatment.
For each cycle in phase 2 you have:
- BT1718 once a week for the first 3 weeks
- a week without treatment
You might have treatment for up to 2 years if it is working and the side effects aren’t too bad.
You give some extra blood samples before, during and after treatment. The researchers will ask if they can take some extra tissue samples before and after treatment. The researchers will look at the samples to:
- measure the levels of BT1718 in your blood
- predict who will benefit from treatment
- a physical examination
- heart trace (
- a test to see how well your kidneys work
- blood tests
- CT scan or MRI scan
To join phase 2, the trial team will do some tests on a sample of tissue (
You have your treatment at the hospital. You might stay overnight so the trial team can keep an eye on you and check any side effects. The trial team will tell you more about how often you stay overnight.
You have a CT scan or MRI scan every 8 weeks. You stop treatment if your cancer has continued to grow. Your doctor will discuss other treatment options with you.
When you finish treatment, you have a check up 1 month later. The trial team continue to follow you up every 3 months at routine clinic appointments or they might phone you or check your medical records to see how you are getting on.
- a drop in the number of blood cells causing an increased risk of infection, breathlessness, bruising and bleeding
- a skin reaction where the nurse injects the drug into a vein causing pain and swelling
- liver changes
- kidney changes
- nerve changes such as pins and needles in the hands or feet or weakness in the arms or legs
- feeling or being sick
- low or high blood pressure causing dizziness or headaches
- dry mouth
- feeling tired
How to join a clinical trial
Professor Udai Banerji
Cancer Research UK
This is Cancer Research UK trial number CRUKD/17/009.